AROA BIOSURGERY LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.515 AUD | +0.98% |
|
-5.50% | -37.95% |
| Apr. 30 | Transcript : Aroa Biosurgery Limited, Q4 2024 Earnings Call, Apr 30, 2024 | |
| Jan. 29 | Transcript : Aroa Biosurgery Limited, Q3 2024 Earnings Call, Jan 30, 2024 |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company does not generate enough profits, which is an alarming weak point.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -37.95% | 117M | - | ||
| +9.48% | 27.43B | B+ | ||
| -28.65% | 3.18B | B- | ||
| -16.08% | 2.53B | C+ | ||
| +19.05% | 2.49B | - | A- | |
| +11.11% | 2.16B | B | ||
| -4.24% | 2.03B | - | ||
| +1.69% | 1.31B | - | ||
| +29.73% | 1.29B | C | ||
| +8.01% | 1.17B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ARX Stock
- Ratings Aroa Biosurgery Limited
